ADMP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 rugs. 2023 @ 22:59):

Stats
Šios dienos apimtis	119 482
Vidutinė apimtis	3.11M
Rinkos kapitalizacija	7.25M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0764
ATR14	$0.190 (30.44%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-23	Dorbin John W. Jr.	Buy	70 000	Employee Stock Option (right to buy)
2023-10-23	Dorbin John W. Jr.	Buy	0
2023-10-16	Cohen Seth	Buy	151 416	Employee Stock Option (right to buy)
2023-10-16	Cohen Seth	Buy	0
2023-09-15	Versi Ebrahim	Buy	729 200	Common Stock

INSIDER POWER
93.18
Last 88 transactions
Buy: 1 947 813 \| Sell: 1 308 563

Tūris Koreliacija

Ilgas: -0.04 (neutral)

Trumpas: -0.22 (neutral)

Signal:(43.501) Neutral

Adamis Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AGRX	0.964
VLCN	0.956
VRAY	0.949
HAIN	0.947
NDLS	0.944
IONM	0.943
NSTG	0.943
ENSC	0.941
CLPT	0.941
NEXT	0.938

10 Labiausiai neigiamai susiję koreliacijos
ADSE	-0.961
NWLI	-0.96
PRSRU	-0.954
EVLV	-0.942
BTWN	-0.934
STCN	-0.932
CCRC	-0.932
ARNA	-0.931
DSEY	-0.931
DMRC	-0.928

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Adamis Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.15
( neutral )

-0.58
( weak negative )

-0.43
( neutral )

-0.07
( neutral )

0.39
( neutral )

-0.22
( neutral )

Adamis Pharmaceuticals Finansinės ataskaitos

Annual	2022
Pajamos:	$4.76M
Bruto pelnas:	$-1.43M (-30.10 %)
EPS:	$-12.24

FY	2022
Pajamos:	$4.76M
Bruto pelnas:	$-1.43M (-30.10 %)
EPS:	$-12.24

FY	2021
Pajamos:	$2.21M
Bruto pelnas:	$-4.66M (-211.14 %)
EPS:	$-0.320

FY	2020
Pajamos:	$16.53M
Bruto pelnas:	$1.63M (9.88 %)
EPS:	$-0.640

Financial Reports:

No articles found.

Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.